Status:
COMPLETED
Second Echelon Node Study With Methylene Blue
Lead Sponsor:
Mayo Clinic
Conditions:
Breast Cancer
Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators plan to study the ability to identify the lymph nodes beyond the sentinel lymph node that may harbor cancer using methylene blue dye.
Detailed Description
After lymphatic mapping of the SLN with Tc-99 sulfur colloid only, the second-echelon lymphatic mapping was then performed with methylene blue dye by injecting the SLN with 0.05-0.10 cc non dilute met...
Eligibility Criteria
Inclusion
- Histologically confirmed primary cutaneous melanoma located on the extremity or trunk
- Patients with clinically stage I-II melanoma
- Histologically confirmed invasive ductal or lobular carcinoma
- Patient undergoing surgical treatment of breast primary and sentinel lymph node biopsy- clinically node negative
Exclusion
- Melanoma located on the head or neck, uveal or mucosal
- Previous surgery or radiation in or near the sentinel lymph node biopsy nodal basin
- Preoperative biopsy proven regional lymph node involvement
- Failure of lymphatic mapping with radioactive colloid
- Women who are pregnant or nursing
- Prior ipsilateral axillary surgery or radiation
- Inflammatory breast cancer
- No lymph node identified in the ipsilateral breast during pathologic review of the mastectomy specimen
- Stage IV breast cancer
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01823172
Start Date
April 1 2013
End Date
November 1 2013
Last Update
March 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905